drugset
drugset / Trial / NCT01648699

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

NCT01648699 ↗

Phase 4 Terminated 20 enrolled Janssen Pharmaceutica
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.

Timeline

Start
2010-04
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 8 mg Oral
Subject Hydromorphone Other / unclassified 12 mg Oral
Subject Hydromorphone Other / unclassified 16 mg Oral
Subject Hydromorphone Other / unclassified 20 mg Oral
Subject Hydromorphone Other / unclassified 24 mg Oral
Subject Hydromorphone Other / unclassified 32 mg Oral
Subject Hydromorphone Other / unclassified 36 mg Oral
Subject Hydromorphone Other / unclassified 40 mg Oral

Indications

No indication recorded.